Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05494762 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by BeiGene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT05494762 is a Phase 1 study that was terminated before completion, run by BeiGene. The registered enrollment target is 55 participants.
The verdict
NCT05494762, a Phase 1 study, was terminated before completion, sponsored by BeiGene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid tumors.
Interventions
- DRUG Tislelizumab
- DRUG BGB-B167
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-08-25 |
| Est. Completion | 2025-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05494762
The ClinicalTrials.gov registry entry for NCT05494762 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tislelizumab is the first listed.
NCT05494762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05494762 about?
NCT05494762 is a clinical study titled "Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors". This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid tumors.
What is the current status of trial NCT05494762?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2022-08-25. Estimated completion is 2025-02-24.
What interventions are being tested in trial NCT05494762?
The interventions under investigation include: Tislelizumab (DRUG), BGB-B167 (DRUG).
Who is sponsoring clinical trial NCT05494762?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.